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Scheme S1. General strategy for the synthesis of Cbz-N-capped ornithine, lysine, arginine and homoarginine 
diphenylphosphonates. 
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Scheme S2. General strategy for the synthesis of Cbz-N-capped thioarginine diphenylphosphonate. 
 
4-Chlorobutanal (S2.1). Oxalyl chloride (0.1 mol) was dissolved in freshly distilled dry dichloromethane
(40 mL). The mixture was cooled to -60ºC and the solution of DMSO (0.27 mol) in dichloromethane (50
mL) was added dropwise. After 15 minutes 4-chlorobutan-1-ol (0.06 mol) dissolved in dichloromethane
(50 mL) was added dropwise. The reaction was performed for 20 minutes and quenched by slow addition
of trimethylamine (0.3 mol) followed by the addition of saturated ammonium chloride solution (100 mL).
After the organic fraction was separated, aqueous phase was extracted with dichloromethane (3 × 50 mL).
The combined organic fractions were washed with 5% citric acid, water and brine, dried over MgSO 4,
filtered and evaporated to dryness yielding final product (73%) as pale yellow oil. 1H NMRH NMR (300
MHz, CDCl3): δ 1.66-1.73 (m, 2H), 2.61-2.68 (m, 2H), 3.38-3.68 (m, 2H), 9.94 (s, 1H).  
Benzyl  (4-chloro-1-(diphenoxyphosphoryl)butyl)carbamate (S2.2).  4-chlorobutanal  (0.037  mol),  benzyl
carbamate  (0.037  mol)  and  triphenyl  phosphite  (0.037  mol)  were  dissolved  in  freshly  distilled  dry
dichloromethane  (20  mL)  followed  by  an  addition  of  copper  triflate  (0.004mol).  The  reaction  was
performed for  24 h  at  room temperature.  Next,  the  volatile  components  of  the  reaction mixture  were
removed under reduced pressure. The resulting oil was dissolved in methanol and left for crystallization at -
20 ºC yielding product (21%) as white solid. mp. 105-110ºC. 31P NMR (121 MHz, CDCl3): δ 18.68 (s). 1H
NMRH NMR (300 MHz, CDCl3): δ 1.91-2.03 (m, 4H), 3.59 (t, J = 5.6 Hz, 2H), 4.44-4.57 (m, 1H), 5.10*
(d, J = 12.2 Hz, 1H), 5.16* (d, J = 12.2 Hz, 1H), 5.28 (d, J = 10.1 Hz, 1H), 7.08-7.35 (m, 15H). 
Benzyl  (4-(carbamimidoylthio)-1-(diphenoxyphosphoryl)butyl)carbamate (8).  Benzyl  (4-chloro-
1(diphenoxyphosphoryl)butyl)carbamate (0.001 mol) and thiourea (0.0012 mol) were dissolved in freshly
distilled dry ethanol and the mixture was refluxed for 48 h. Next, the volatile components of the reaction
mixture were removed under reduced pressure.  The resulting oil  was dissolved in minimal  volume of
methanol and diethyl ether was added. The solution was left for crystallization at 4 ºC yielding product
(37%) as white solid. mp. 107 ºC.  31P NMR (121 MHz,  DMSO-d6):  δ 18.94 (s).  1H NMR (300 MHz,
DMSO-d6): δ 1.74-1.98 (m, 4H), 3.58-3.60 (m, 2H), 4.19-4.26 (m, 1H), 4.97* (d, J = 12.6 Hz, 1H), 5.03* (d,
J = 12.4 Hz, 1H), 6.89-7.33 (m, 19H), 8.02 (d, J = 9.6 Hz, 1H). 13C NMR (75 MHz, DMSO-d6): δ 26.53,
29.03 (d, J = 15.0 Hz), 45.09, 48.26 (d, J = 159.3 Hz), 66.40, 120.97 (dd, J = 3.7/16.1 Hz), 125.78 (d, J =
10.3 Hz), 128.30 (d, J = 13.2 Hz), 128.86, 130.37 (d, J = 5.4 Hz), 137.32, 150.29 (d, J = 9.3 Hz), 156.77,
184.36. MS (ESI): 
514.1 (M+1).  
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Scheme S3. General strategy for the synthesis of Cbz-N-capped glutamine dip[henylphosphonate. 
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Scheme S4. General strategy for the synthesis of Cbz-N-capped4-guanidinophenylalanine diphenylphosphonate 
derivatives. 
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 Scheme S5. General strategy for the synthesis of Cbz-N-capped 4-guanidinophenylglycine diphenylphosphonate 
derivatives. 
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Scheme S6. General strategy for the synthesis of Cbz-N-capped 4-amidinophenylglycine diphenylphosphonate. 
 
 
 
 
  
O
O
O
O
O
O
OH
O
KOH/ MeOH
dioxane, 80oC
O
O
NH2
O
SOCl2, DCE, reflux
NH3/MeOH, DCM
CN
O
O
TFAA, pyridine
dioxane, 0oC
CN
OH
LiBH4
THF/EtOH
Swern ox.CN
O
N
H
P
O
O
O
O
O Cbz-NH2, P(OPh)3AcOH, reflux
CN
HCl(g), EtOH, CHCl3, 0oC
N
H
P
O
O
O
O
O
HN NH2
NH3/MeOH, reflux
S7.1 S7.2 S7.3
S7.4S7.52223
Scheme S7. General strategy for the synthesis of  Cbz-N-capped4-amidinonaphthylglycine diphenylphosphonate.
6-(Methoxycarbonyl)-2-naphthoic  acid (S7.1).  Dimethyl  naphthalene-2,6-dicarboxylate  (0.02  mol)  was
heated to  80 ºC in dioxane (30 mL) until  completely dissolved.  Next,  a  solution of  KOH (1.32 g)  in
methanol (10 mL) was added dropwise resulting in precipitation of white solid. The reaction as performed
at 90 ºC for 2 h. White solid was filtered, washed with diethyl ether and dissolved in water (200 mL)
followed by addition of 2M HCl until pH reached 3.0. Precipitated product was filtered, washed with water
and dried on air yielding final product as white solid (83%).  1H NMR (300 MHz, DMSO-d6):  δ 3.93 (s,
3H), 8.01-8.06 (m, 2H), 8.19-8.23 (m, 2H), 8.66 (s, 2H), 13.26 (s, 1H). 
 
Methyl 6-carbamoyl-2-naphthoate (S7.2). Into the solution of 6-(methoxycarbonyl)-2-naphthoic acid (0.016
mol)  in  1,2-dichloroethane (120 mL),  thionyl  chloride (60 mL) was added.  The reaction mixture  was
refluxed for 3h until.  Next,  the volatile elements of the reaction mixture were removed under reduced
pressure, redissolved in dry toluene (120 mL) and evaporated to dryness. The resulting oil was dissolved in
dry dichloromethane (60 mL) and the solution of 7M ammonia in methanol (5 mL) was added. The reaction
was performed at room temperature for 3h. The precipitated product was filtered yielding final product as
white solid (93%). 1H NMR (300 MHz, DMSO-d6): δ 3.92 (s, 3H), 8.02 (d, J = 8.5 Hz, 2H), 8.11 (d, J =
8.6, 1H), 8.19 (d, J = 8.6 Hz, 2H), 8.55 (s, 1H), 8.66 (s, 1H).  
 
Methyl  6-cyano-2-naphthoate (S7.3).  Methyl  6-carbamoyl-2-naphthoate  (0.01  mol)  was  suspended  in
dioxane (35 mL) followed by an addition of dry pyridine (2.4 mL). The reaction mixture was cooled in ice
bath and trifluoroacetic anhydride (20 mL) was added dropwise. The reaction was let to equilibrate to room
temperature. After 48h the reaction mixture was diluted with water (300 mL) and extracted with ethyl
acetate (3×75 mL). The combined organic extracts were washed with water, dried over MgSO4, evaporated
to dryness yielding product as white solid (44%). 1H NMR (300 MHz, DMSO-d6): δ 3.93 (s, 3H), 7.87 (dd,
J =  1.6/8.5  Hz,  1H),  8.08-8.18  (m,  2H),  8.33  (d,  J =  8.7  Hz,  1H),  8.65  (s,  1H),  8.72  (s,  1H).  6-
(Hydroxymethyl)-2-naphthonitrile (S7.4). Methyl 6-cyano-2-naphthoate (0.008 mol) was dissolved in THF
(100 mL) and LiBH4 (0.09 mol) was added. The resulting suspension was intensively stirred for 30 minutes
followed by an addition of ethanol (100mL). The reaction was performed for at room temperature for 24h.
Next,  NaHCO3 (5%  aq)  was  slowly  added  until  the  reaction  mixture  was  transparent.  The  volatile
components were removed under reduced pressure and the resulting aqueous fraction was extracted with
CHCl3 (3×100 mL). Combined organic extracts were washed with water and brine, dried over MgSO 4,
filtered  end  evaporated  to  dryness  yielding  product  as  pale  beige  solid  (96%).  1H NMR (300 MHz,
CDCl3): δ 2.02 (s, 1H), 4.91 (s, 2H), 7.60 (dd, J = 1.3/8.5 Hz, 1H), 7.87-7.91 (m, 3H), 8.20 (s, 1H). 
 
6-Formyl-2-naphthonitrile (S7.5)  was  synthesized  using  method  described  for  S2.1  yielding  target
compound as pale yellow oil (95%), which was directly used in the next step.  
 
Benzyl ((6-cyanonaphthalen-2-yl)(diphenoxyphosphoryl)methyl)carbamate (22). 6-Formyl-2-naphthonitrile
(0.0055 mol),  benzyl  carbamate  (0.0055 mol)  and triphenyl  phosphite (0.0055 mol)  were dissolved in
glacial acetic acid (6 mL). The reaction was performed at 80 ºC for 2h. The volatile elements were removed
under reduced pressure and resulting oil was dissolved in methanol and left for crystallization at -20 ºC.
The product was obtained as white solid (25%). 31P NMR (121 MHz, CDCl3): δ 14.53 (s). 1H NMR (300
MHz, CDCl3): δ 5.07* (d, J = 12.1 Hz, 1H), 5.15* (d, J = 12.3 Hz, 1H), 5.76 (dd, J = 9.1/22.8 Hz, 1H), 6.19
(q, J = 8.9 Hz, 1H), 6.87-7.37 (m, 15H), 7.59 (dd, J = 1.0/8.5 Hz, 1H), 7.72-7.88 (m, 3H), 7.99 (s, 1H), 8.19
(s, 1H,). 
13C NMR (75 MHz, CDCl3):  δ 53.02 (d,  J = 157.4 Hz), 67.76, 110.08, 119.00, 120.31 (dd,  J = 4.3/14.0
Hz), 125.61 (d, J = 6.6 Hz), 127.00, 127.42, 127.48, 127.57, 127.67, 128.27, 128.42, 128.60, 129.48 (d, J =
10.3 Hz), 129.82 (d, J = 8.1 Hz), 131.98, 133.83, 134.44, 135.39, 135.82, 149.91 (d, J = 9.6 Hz), 150.17 (d,
J = 9.3 Hz), 155.68 (d, J = 11.4 Hz). 
 
Benzyl  ((6-carbamimidoylnaphthalen-2-yl)(diphenoxyphosphoryl)methyl)carbamate (23).  Benzyl
((6cyanonaphthalen-2-yl)(diphenoxyphosphoryl)methyl)carbamate  (0.9  mmol)  was  dissolved  in  the
mixture of dry ethanol (1.7 mL) and dry chloroform (16 mL). The solution was saturated with gaseous HCl,
sealed and kept at -20 ºC for 4 days. Next, diethyl ether (100 mL) was added and precipitated iminoether
was filtered and dried in vacuum over P2O5. Next, collected iminoether was dissolved in methanol (50 mL)
followed by an addition of 7M ammonia in methanol (0.15 mL). The reaction was performed at room
temperature for 45 min prior evaporation of volatile components. Resulting oil was dissolved in methanol
and  refluxed  for  8  h.  The  solvent  was  evaporated  and  the  product  was  purified  on  Silica  Gel
(CHCl3:MeOH:AcOH/90:10:1;  v/v/v)  yielding  final  product  as  pale  beige solid  (29%).  31P NMR (121
MHz, DMSO-d6): δ 15.85 (s). 1H NMR (300 MHz, DMSO-d6): δ 5.06* (d, J = 12.5 Hz, 1H), 5.16* (d, J =
12.3 Hz, 1H), 5.83 (d, J = 22.8 Hz), 6.97-7.35 (m, 15H), 7.89 (dd, J = 8.4/22.1 Hz, 2H), 8.08 (t, J = 7.8 Hz,
2H), 8.27 (s, 1H), 8.44 (s, 1H), 10.37 (br s, 5H). 13C NMR (75 MHz, DMSO-d6): δ 50.89 (d, J = 155.2 Hz),
66.79, 120.73 (d,  J = 3.8 Hz), 124.75, 125.85 (d,  J = 6.3 Hz), 127.94, 128.44, 128.86, 129.04, 129.71,
130.35 (d, J = 3.8 Hz), 131.85, 134.79, 135.27, 137.09, 166.31, 177.20. MS (ESI): m/z = 566.8 (M+)  
 
 
 
Scheme S8. General strategy for the synthesis of  Cbz-N-capped 4-guanidinophenylglycine diphenylphosphonate 
derivatives. 
 
 
Benzyl ((4-(1H-pyrazol-1-yl)phenyl)(diphenoxyphosphoryl)methyl)carbamate (24). Yield: 53%. 31P NMR 
(121 MHz, CDCl3): δ 15.06 (s). 1H NMR (300 MHz, CDCl3): δ 5.05* (d, J = 12.2 Hz, 1H), 5.13* (d, J = 
12.3 Hz, 1H), 5.61 (dd, J = 9.4/22.2 Hz, 1H), 6.05 (dd, J = 3.6/9.6 Hz, 1H), 6.47 (t, J = 1.8 Hz, 1H), 
6.916.94 (m, 2H), 7.10-7.32 (m, 15H), 7.52-7.60 (m, 2H), 7.71-7.73 (m, 3H), 7.91 (d, J = 2.5 Hz, 1H). 13C 
NMR (75 MHz, CDCl3): δ 53.39 (d, J = 157.7 Hz), 67.66, 107.92, 119.37, 120.40 (dd, J = 4.1/8.9 Hz), 
125.50 (d, J = 3.0 Hz), 126.75, 128.30 (d, J = 10.9 Hz), 128.60, 129.35 (d, J = 6.3 Hz), 132.37, 135.90, 
140.35, 141.38, 150.00 (d, J = 10.0 Hz), 155.45 (d, J = 10.5 Hz). 
 
Benzyl ((4-(1H-benzo[d]imidazol-1-yl)phenyl)(diphenoxyphosphoryl)methyl)carbamate (25). Yield: 18%. 
31P NMR (121 MHz, CDCl3): δ 14.69 (s). 1H NMR (300 MHz, CDCl3): δ 5.16-5.25 (m, 2H), 5.74 (dd, J =
10.2/25.8 Hz, 1H), 6.30 (d, J = 7.2 Hz, 1H), 7.12-8.04 (m, 24H). 
 
Benzyl ((diphenoxyphosphoryl)(4-(4-methylpiperazin-1-yl)phenyl)methyl)carbamate (26). Yield: 31%. 31P
NMR (121 MHz, CDCl3): δ 16.02 (s). 1H NMR (300 MHz, CDCl3): δ 2.35 (s, 3H), 2.57 (t, J = 4.8 Hz,
4H), 3.21 (t, J = 4.7 Hz, 4H), 5.04* (d, J = 12.1 Hz, 1H), 5.14* (d, J = 12.1 Hz, 1H), 5.49 (dd, J = 10.1/21.7
Hz, 1H), 5.86 (d, J = 7.4 Hz, 1H), 6.83-7.38 (m, 19H). 13C NMR (75 MHz, CDCl3): δ 46.10, 48.68, 52.34
(d,  J = 163.5 Hz), 54.98, 67.48, 116.02, 120.50 (t,  J = 4.4 Hz), 124.54, 125.28 (d,  J = 5.1 Hz), 128.27,
128.56, 129.13 (d, J = 6.7 Hz), 129.66 (d, J = 8.5 Hz), 151.45. 
 
Benzyl ((diphenoxyphosphoryl)(4-morpholinophenyl)methyl)carbamate (27). Yield: 48%.  31P NMR (121
MHz, CDCl3): δ 15.88 (s). 1H NMR (300 MHz, CDCl3): δ 3.15 (t, J = 4.9, 4H), 3.85 (t, J = 4.7 Hz, 4H),
5.04* (d, J = 12.2 Hz, 1H), 5.13* (d, J = 12.2 Hz, 1H), 5.50 (dd, J = 10.1/21.6 Hz, 1H),5.89 (d, J = 8.4 Hz,
1H), 6.85-7.38 (m, 19H).  13C NMR (75 MHz,  CDCl3):  δ 49.01, 52.33 (d,  J = 159.7 Hz), 66.82, 67.49,
117.71, 120.49 (t, J = 4.6 Hz), 125.01, 125.29 (d, J = 5.1 Hz), 128.24 (d, J = 6.3 Hz), 128.56, 129.18 (d, J =
6.6 Hz), 129.67 (d, J = 8.0 Hz), 150.20 (d, J = 9.6 Hz), 151.48, 155.40. 
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Benzyl  ((2R)-6-amino-1-(((2R)-1-((5-amino-1-(diphenoxyphosphoryl)pentyl)amino)-5-guanidino-
1oxopentan-2-yl)amino)-1-oxohexan-2-yl)carbamate (36). 1H NMR (400 MHz, DMSO-d6):  δ 8.31 (d,  J =
7.7 Hz, 1H), 7.78 – 7.62 (m, 4H), 7.69 – 7.58 (m, 1H), 7.55 – 7.33 (m, 4H), 7.30 – 7.24 (m, 4H), 7.18 –
7.07 (m, 6H), 6.77 – 6.71 (m, 6H), 5.12 – 4.95 (m, 2H), 4.41 – 4.30 (m, 1H), 4.23 – 4.11 (m, 1H), 4.07 –
3.88 (m, 1H), 3.21 – 2.97 (m, 4H), 2.74 – 2.63 (m, 2H), 1.82 – 1.75 (m, 2H), 1.72 – 1.62 (m, 2H), 1.65 –
1.36 (m, 11H), 1.30 – 1.09 (m, 4H).
.  31P NMR (243 MHz, DMSO-d6):  δ 18.21 (s, 52%), 18.78 (s,48%). HRMS: calcd for (C37H53N8O7P)Na+,
775.3673; found, 775.3675. HPLC: tR = 13.85 min. 
 
 
Benzyl  ((2R)-6-amino-1-(((2R)-1-((1-(diphenoxyphosphoryl)-4-guanidinobutyl)amino)-5-guanidino-
1oxopentan-2-yl)amino)-1-oxohexan-2-yl)carbamate (37)  1H NMR (400 MHz, DMSO-d6)  δ 9.33 (s, 1H),
8.20 (d, J = 7.5 Hz, 1H), 7.95 (d, J = 7.9 Hz, 1H), 7.74 – 7.65 (m, 4H), 7.64 – 7.58 (m, 1H), 7.42 – 7.37 (m,
1H), 7.36 – 7.24 (m, 8H), 7.14 – 7.08 (m, 5H), 6.74 – 6.68 (m, 7H), 5.06 – 4.89 (m, 2H), 4.30 – 4.23 (m,
1H), 4.17 – 4.08 (m, 1H), 4.00 – 3.91 (m, 1H), 3.16 – 2.98 (m, 4H), 2.77 – 2.61 (m, 2H), 1.76 – 1.64 (m,
2H), 1.62 – 1.52 (m, 2H), 1.52 – 1.42 (m, 9H), 1.34 – 1.17 (m, 3H)..  31P NMR (162 MHz, DMSO-d6):  δ
18.15 (s, 54%), 18.72 (s, 46%). HRMS: calcd for (C37H53N10O7P)Na+, 803.3734; found, 803.3737. HPLC: tR
= 13.14 min. 
 
 
Benzyl  ((2R)-6-amino-1-(((2R)-1-((1-(diphenoxyphosphoryl)-2-(4-guanidinophenyl)ethyl)amino)-
5guanidino-1-oxopentan-2-yl)amino)-1-oxohexan-2-yl)carbamate (38). 1H NMR (400 MHz, DMSO-d6):  δ
10.18 (s, 1H), 8.85 (s, 1H), 8.14 (d, J = 7.8 Hz, 1H), 7.73 (s, 3H), 7.57 (s, 3H), 7.46 (s, 1H), 7.44 (s, 1H),
7.41 – 7.24 (m, 10H), 7.22 (d, J = 1.2 Hz, 1H), 7.21 – 7.15 (m, 4H), 7.12 – 7.04 (m, 5H), 5.01 – 4.93 (m,
2H), 4.54 – 4.38 (m, 1H), 4.19 – 4.12 (m, 1H), 4.04 – 3.88 (m, 1H), 3.41 – 3.30 (m, 2H), 3.29 – 3.15 (m,
2H), 3.11 – 2.98 (m, 2H), 2.78 – 2.65 (m, 2H), 1.78 – 1.66 (m, 1H), 1.63 – 1.53 (m, 2H), 1.52 – 1.42 (m,
6H), 1.39 – 1.25 (m, 3H). 31P NMR (162 MHz, DMSO-d6): δ 18.12 (s, 54%), 18.50 (s, 46%). HRMS: calcd
for (C41H53N10O7P)Na+, 851.3734; found, 851.3740. HPLC: tR = 14.91 min. 
 
 
Benzyl  ((R)-6-amino-1-(((R)-1-(((4-carbamimidoylphenyl)(diphenoxyphosphoryl)methyl)amino)-
5guanidino-1-oxopentan-2-yl)amino)-1-oxohexan-2-yl)carbamate (39). 1H NMR (400 MHz,  DMSO-d6):
10.08 (s, 1H), 8.71 (s, 1H), 8.11 – 8.07 (m, 1H), 7.81 – 7.72 (m, 7H), 7.45 – 7.21 (m, 11H), 7.15 (d, J = 1.5
Hz, 1H), 7.11 – 7.03 (m, 4H), 7.00 – 6.92 (m, 5H), 5.05 – 4.90 (m, 2H), 4.49 – 4.36 (m, 1H), 4.21 – 4.18
(m, 1H), 4.07 – 3.85 (m, 1H), 3.47– 3.41 (m, 2H), 3.31 – 3.22 (m, 2H), 2.80 – 2.71 (m, 2H), 1.82 – 1.72 (m,
1H), 1.65 – 1.51 (m, 2H), 1.48 – 1.40 (m, 6H), 1.34 – 1.21 (m, 3H).31P NMR (162 MHz, DMSO-d6)  δ
18.18(s, 51%), 18.47 (s, 49%). HRMS: calcd for (C40H50N9O7P)Na+, 822.3469; found, 822.3477. tR = 14.71
min. 
 
 
 
 SPPS Cbz-Lys(Boc)-Arg(Pbf)-Arg(Pbf)-OH
O
N
H xHCl
EDC, HOBt, DIPEA
Cbz-Lys-Arg-Arg-H
1. LiAlH4, THF
2. TFA/TIPS/H2O
3.HPLC purification 40
Scheme S9. Synthesis of reference peptide aldehyde inhibitor (40) 
Figure S1. Enzyme (WNV NS2B/NS3) reaction progress  curves with in the presence of inhibitor 38 in different
concentrations (A). Plot of kobs as function of inhibitor (38) concentration (B). Substrate used: Pyr-RTKR-AMC (C=20
µM, KM= 59 µM).
Mathematical Inhibition Model.
Mechanism of inhibitory action can be expressed as this simplified equation:
E+ I
k 1
→
k−1
←
E∙ I k2
→
E−I  
where  Ki is  the  reversible  enzyme–inhibitor  complex  dissociation  constant,  and  k2 is  the
inactivation rate  constantrate  of irreversible  complex (E-I)  formation.  Thus the k2/Ki  value for
irreversible  phosphonic-type inhibitors  fully reflects  their  potency of action towards the target
serine protease.
The inhibitory activity of the compounds was determined by the progress curve method. First the
data from nonlinear progress curves with time dependent inhibitors were fit to eq.1 to obtain the
first-order rate constant (kobs): 
In  case  of irreversible  inhibitors vs is  zero
The  second-order  rate  constants  (k2/KI)  and  (KI)app values  were  calculated  using  hyperbolic
regression according to equation 32: 
 KI  values were calculated according to 
equation 3:
[ P ] =vs t+
v i−vs
kobs
[1−e( −kobs t )]    
(1)
[P] is the product concentration at time  t,  vi is
the  initial  velocity,  and  vs is  the  steady  state
velocity
[P ]=
v i
kobs
[1−e(−kobs t) ]    
(2)
k obs=
k2[ I ]
❑❑❑❑❑+[I ]
(32)
kobs is the first-order rate constant at known inhibitor
❑❑
❑❑❑
❑
❑❑
 Stability in assay buffer.  A stock solution of compound (38) (10 mM in acetonitrile) was added to the
assay buffer (50 mM Tris, 1 mM Chaps, 20% glycerol, pH 8.5) to make a final concentration of 2 mg/mL
and incubated at 37°C. The resulting mixture was subjected to HPLC analysis to determine compound
stability using a Discovery® BIO Wide Pore C8 HPLC Column (250 mm × 4.6 mm, 10 μm) with a 1 mL/
min flow rate, gradient 0−100% [0.05% TFA in acetonitrile] in [0.05% TFA in water] over a period of 15
min. 
Obtained results are presented in Table S1 and Figure S2. Over 6 hours we observed degradation of ~13%
of  compound  38.  However during  enzyme  inhibition  assay  time  inhibitor  degradation  is  almost
unnoticeable (~1%). As we expect degradation product is corresponding monoester of compound 38. This
degradation process is probably caused by basic character of used buffer (pH 8.5).   
Table S1. Stability of 38 in assay buffer (50 mM Tris, 1 mM Chaps, 20% glycerol, pH 8.5)
Time[h] % of initial inhibitorconcentration
0.0 100
0.5 98,93
1.0 98,12
1.5 96,27
2.0 95,19
2.5 95,04
3.0 93,35
3.5 91,90
4.0 91,11
4.5 88,43
5.0 86,99
5.5 86,84
6.0 86,73
 Figure S2. Chromatograms from stability of inhibitor 38 in assay buffer
 Table S2. Activity of tested compounds against trypsin, cathepsin G and HAT protease.
No. Compound Trypsin CatG HAT
36 Cbz-Lys-Arg-LysP(OPh)2 8%a 2% 2%
37 Cbz-Lys-Arg-ArgP(OPh)2 7% 3% 2%
38 Cbz-Lys-Arg-(4-GuPhe)P(OPh)2 4% 7% 5%
39 Cbz-Lys-Arg-(4-GuPhg)P(OPh)2 5% 9% 6%
a percent of inhibition was calculated for compounds which displayed low activity toward protease after 30 min 
incubation at 37º C at inhibitor concentration 25μM
Figure S3. Mechanism of serine proteases inhibition by α-aminoalkylphosphonate diphenyl esters
Figure S34. Localization of phosphonate (green) moiety near catalytic serine residue (yellow)
Figure S4. Interactions of 4-guanidinephenylalanine moiety with enzyme tyrosine residues
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Figure S5.1H NMR and 31P NMR of inhibitor 37
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Figure S65.1H NMR and 31P NMR of inhibitor 38
Figure S76. HRMS spectra from coupling reaction of 34 with dipeptide Cbz-Lys(Boc)-Arg(Pbf)-OH  
Figure S87. Inhibitor 38 HRMS spectra 
Figure S98. HRMS spectra from coupling reaction of 35 with dipeptide Cbz-Lys(Boc)-Arg(Pbf)-OH  
Figure S109. Inhibitor 39 HRMS spectra 
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